Related Experiment Videos
Acquired sideroblastic anaemia induced by a copper-chelating agent
A R Perry1, A Pagliuca, E J Fitzsimons
1Department of Haematology, King's College Hospital, London, UK.
International Journal of Hematology
|July 1, 1996
Summary
Triethylene tetramine dihydrochloride (trientine) can cause acquired sideroblastic anemia. Reducing the trientine dose improved the anemia, suggesting a link to mitochondrial iron metabolism.
Area of Science:
- Hematology
- Pharmacology
- Biochemistry
Background:
- Acquired sideroblastic anemia is often linked to drug-induced inhibition of heme synthesis.
- Wilson's disease treatment involves copper-chelating agents like triethylene tetramine dihydrochloride (trientine).
Observation:
- A patient developed secondary acquired sideroblastic anemia after receiving trientine for Wilson's disease.
- The patient's anemia resolved upon reduction of the trientine dosage.
Findings:
- Trientine administration was associated with the development of acquired sideroblastic anemia.
- The mechanism remains unclear, but trientine did not inhibit key mitochondrial heme synthesis enzymes.
- Trientine may directly impact mitochondrial iron metabolism, leading to sideroblastic anemia.
Implications:
- This case highlights a potential adverse effect of trientine, requiring careful monitoring in patients.
- Further research is needed to elucidate the precise mechanism of trientine-induced sideroblastic anemia.
- Understanding this mechanism could inform safer therapeutic strategies for Wilson's disease and related conditions.